Novo Nordisk said on Wednesday it was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs. U.S. regulations allow ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ... get ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

Novo Nordisk's semaglutide trial showed 62.9% of patients experienced resolution of symptoms with no worsening of scarring. "Novo Nordisk's Weight-Loss Drug Helps Improve Symptoms of Liver Disease, ...

All doses of Novo Nordisk’s (NVO) diabetes and obesity treatments are listed as available on the FDA’s drug shortage list as of ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...